Drug Trial Radar · NCT01287741
A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Last checked: Nov 20, 2026Latest source record: Apr 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,418
Actual
Start
Jul 26, 2011
Primary completion
Apr 29, 2016
Study completion Jan 31, 2018
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Fondazione Italiana Linfomi - ETS
- First posted
- Feb 1, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label, randomized, parallel group study will evaluate the efficacy and safety of obinutuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone or prednisone (CHOP) chemotherapy versus rituximab (MabThera/Rituxan) with CHOP in previously untreated participants with cluster of differentiation 20 (CD20)-positive diffuse large B-cell lymphoma (DLBCL). Participants will be randomized to receive either obinutuzumab 1000 milligrams (mg) intravenously (IV) every 21 days or rituximab 375 milligrams per square meter (mg/m\^2) IV every 21 days for 8 cycles, in addition to 6-8 cycles of CHOP chemotherapy IV every 21 days. Participants randomized to the obinutuzumab arm will receive an additional two doses on Days 8 and 15 of Cycle 1. Anticipated time on study treatment is 24 weeks.
Conditions
- Diffuse Large B-Cell Lymphoma
Interventions
RituximabDrug
Rituximab at a dose of 375 mg/m\^2, administered by intravenous (IV) infusion on Day 1 of each 21-day cycle for 8 cycles.
ObinutuzumabDrug
Obinutuzumab 1000 mg IV infusion, administered on Day 1 of each 21-day cycle for 8 cycles. During Cycle 1, obinutuzumab was also infused on Days 8 and 15.
CyclophosphamideDrug
Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle.
DoxorubicinDrug
Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle.
VincristineDrug
Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.
PrednisoneDrug
Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Median Time to Progression-Free Survival (PFS), Investigator-AssessedTime frame: Baseline up to approximately 6.5 years (up to 31 January 2018)
Locations
235 sites in 29 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Ironwood Cancer TX & Rsch Ctrs
Chandler, Arizona
Arizona Oncology
Tucson, Arizona
California Cancer Associates for Research & Excellence, Inc.
Encinitas, California
cCare
Encinitas, California
UCLA - School of Medicine; Division of Hematology/Oncology
Los Angeles, California
Rocky Mountain Cancer Center - Aurora
Aurora, Colorado
Florida Cancer Specialists; Department of Oncology
Fort Myers, Florida
Florida Cancer Specialists; Saint Petersburg
St. Petersburg, Florida
Central Georgia Cancer Care PC
Macon, Georgia
Illinois Cancer Care, P.C. - Galesburg
Galesburg, Illinois
Joliet Oncology-Hematology; Associates, Ltd.
Joliet, Illinois
Cancer Care & Hematology; Specialists of Chicagoland
Niles, Illinois
Carle Cancer Center
Urbana, Illinois
Mercy Oncology / Hematology Center; Oncology
Portland, Maine
Park Nicollet Clin-Cancer Ctr
Saint Louis Park, Minnesota
Minnesota Oncology Hematology Woodbury
Woodbury, Minnesota
New York Oncology Hematology, P.C.
Albany, New York
Mecklenburg Medical Group Charlotte
Charlotte, North Carolina
Forsyth Regional Cancer Center; Piedmont Hematology/Oncology Associates
Winston-Salem, North Carolina
Signal Point Clinical; Research Center, LLC
Middletown, Ohio
Cleveland CL N Coast Cancer Cr
Sandusky, Ohio
Willamette Valley Cancer Insitute and Research Center
Springfield, Oregon
Medical University of SC (MUSC)
Charleston, South Carolina
South Carolina Oncology Associates - SCRI
Columbia, South Carolina
Chattanooga Oncology and Hematology Associates, PC
Chattanooga, Tennessee
Tennessee Onc., PLLC - SCRI
Nashville, Tennessee
Texas Oncology, Pa - Amarillo
Amarillo, Texas
Texas Oncology-Fort Worth 12th Ave
Fort Worth, Texas
MD Anderson Cancer Center Department of Lymphoma & Myeloma
Houston, Texas
Cancer Care Centers of South Texas-HOAST - San Antonio
New Braunfels, Texas
Virginia Cancer Institute
Richmond, Virginia
Blue Ridge Cancer Care
Roanoke, Virginia
Virginia Cancer Specialists - Winchester
Winchester, Virginia
Northwest Medical Specialties
Tacoma, Washington
Wenatchee Valley Hospital & Clinics
Wenatchee, Washington
Instituto Damic
Córdoba, Argentina
Sanatorio Britanico: Hematologia
Rosario, Argentina
Sanatorio Parque de Rosario
Rosario, Argentina
Cairns Base Hospital; Cancer Care Centre
Cairns, Queensland, Australia
Showing 40 of 235 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.